AOD9604

AOD9604 (Anti-Obesity Drug 9604) is a modified fragment of the C-terminus of human growth hormone, specifically the 177–191 sequence with an added tyrosine residue for stability. It was originally developed in Australia as a candidate obesity therapeutic.

AOD9604 is the piece of growth hormone that researchers isolated specifically for its fat-burning signal — without the muscle-growth or blood-sugar effects of full HGH. Think of it as the 'fat-only' fragment.

Mimics the lipolytic (fat-releasing) action of native hGH by stimulating beta-3 adrenergic receptors on adipocytes, increasing lipolysis and inhibiting lipogenesis. Unlike full HGH it does not bind the GH receptor and does not raise IGF-1 or affect glucose tolerance in research models.

Modified C-terminus fragment of HGH. Stimulates lipolysis without affecting blood sugar or IGF-1.

1. AOD9604
2. Incretin and appetite-regulating receptors
3. Slowed gastric emptying and altered satiety signalling
4. Energy-balance and glycaemic research endpoints

A plain-English read on how much published evidence currently exists for AOD9604. These ratings describe the volume and maturity of the literature — not effectiveness, safety, or suitability for any use.

Current limitations: most compounds in this category are studied in preclinical or small-sample settings. Absence of large controlled human trials is the single biggest limitation to keep in mind when reading any summary of AOD9604.

Lyophilized compounds are supplied as a dry powder. Concentration is simply the total amount in the vial divided by the volume of bacteriostatic water added:

Concentration (mg/mL) = total mg in vial ÷ mL of diluent added

Commonly supplied vial sizes

5mg vial

Worked concentration example

5mg + 2mL BAC water → 2.5mg/mL On U-100 insulin syringe:

• • 10 units = 250mcg
• • 20 units = 500mcg

Run your own numbers with the reconstitution calculator — it converts vial size and diluent volume into mg/mL and mcg/mL.

The figures below are reported here descriptively, because they are the values most frequently cited in publicly available research literature and reference material. They are not instructions, not a protocol, and not a recommendation. These compounds are supplied for laboratory research use only and are not approved by the FDA for human consumption.

Commonly cited amounts

250–500mcg daily, subcutaneous (fasted morning preferred)

Commonly cited frequency

Daily, typically AM fasted

Commonly cited study duration

8–12 weeks

Peptides are supplied freeze-dried because peptide bonds degrade far faster in solution than in a dry state. Understanding storage is part of understanding why the powder form exists at all.

• •Lyophilized powder: stored refrigerated, typically stable for months to years.
• •Reconstituted solution: refrigerated at 2–8°C, generally discussed as stable for roughly 30–60 days.
• •Heat and direct light accelerate degradation — vials are kept cool and dark.
• •Reconstituted material is not re-frozen; ice crystal formation disrupts peptide structure.
• •Bacteriostatic water contains 0.9% benzyl alcohol as a preservative, which is what allows multi-day storage after reconstitution.

More detail in the storage & handling guide and how peptide quality is evaluated.

• •Adipocyte lipolysis studies
• •Obesity and body-composition research
• •Cartilage repair models
• •Comparison with HGH Fragment 176-191
• •Metabolic syndrome research

Frequently discussed in fat-loss and recomposition forums as a 'gentle' alternative to HGH-Frag 176-191. People debate whether the added tyrosine meaningfully changes outcomes versus the unmodified fragment. Often listed in cosmetic-injection conversations for localized fat research.

“The fat-burning piece of growth hormone, minus the side effects.”

Commonly paired with CJC-1295/Ipamorelin in body-composition stacks and compared head-to-head with HGH Fragment 176-191 and Tesamorelin.

AOD9604 is a modified hGH 176-191 fragment studied for selective lipolysis without the IGF-1 or glycemic effects of full growth hormone.